U.S. markets closed

Prime Medicine, Inc. (PRME)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
17.65+0.07 (+0.40%)
At close: 04:00PM EST
17.65 0.00 (0.00%)
After hours: 04:01PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close17.58
Bid17.04 x 800
Ask19.19 x 1200
Day's Range16.95 - 17.79
52 Week Range14.52 - 21.73
Avg. Volume219,523
Market Cap1.716B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PRME

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Prime Medicine, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Fair Value
    Economic Moat
View more
  • Simply Wall St.

    We Think Prime Medicine (NASDAQ:PRME) Needs To Drive Business Growth Carefully

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities

    -- New preclinical data in Friedrich’s ataxia and cystic fibrosis provided further proof-of-concept for Prime Editing’s ability to achieve restoration of genetic function ---- New preliminary safety analyses demonstrated no detected off-target activity in Prime Edited Wilson’s disease cells ---- New data leveraging PASSIGE technology demonstrated ability to integrate kilobase-sized DNA in human T cells ---- Additional LNP and AAV delivery data demonstrated efficient in vivo delivery of Prime Edi

  • GlobeNewswire

    Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA. A live audio webcast of